Season 3 - Ep.4: Heart disease in dialysis patients - Substance abuse and heart disease

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.  This episode covers: Cardiology This Week: A concise summary of recent studies Heart disease in dialysis patients Substance abuse and heart disease Snapshots: Pneumopericardium Host: Emer Joyce Guests: Carlos Aguiar, Patrick Mark, Theo Pezel, Stephan Achenbach Want to watch that episode? Go to: https://esc365.escardio.org/event/1794 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Emer Joyce, Nicolle Kraenkel and Theo Pezel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi Aventis, Novo Nordisk, Terumo. Patrick Mark has declared to have potential conflicts of interest to report: lecture/advisory board honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Pharmacosmos, Astellas, GSK, Vifor. Grants from Boehringer Ingelheim, AstraZeneca. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.